Skip Navigation LinksHome > Professional Development > eLearning > Gene Therapy for Severe Combined Immunodeficiency Syndrome (SCID)

Gene Therapy for Severe Combined Immunodeficiency Syndrome (SCID)

Please note: AABB reserves the right to make updates to this program

Thursday, July 26, 2018
2:00 – 3:00 PM (ET) 7:00 – 8:00 PM (GMT)
Master Program Number: 18EL-348 (see program format numbers below under Registration)

Educational Track: Cellular Therapies
Topic:  Technical/Clinical
Intended Audience: Hospitals, Hospital Blood Banks, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research Scientist, Resident/Fellow, Scientists, Students (MD, MT, SBB), Technologist
Teaching Level: Intermediate

Director/ Moderator: Deborah A. Sesok-Pizzini, MD, MBA, CQA(ASQ)CMQ/OE, Chief, Blood Bank and Transfusion Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA
Speaker: Jennifer Heimall, MD, Attending Physician, Division of Allergy and Immunology Service, Children's Hospital of Philadelphia, Philadelphia, PA

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Discuss the development of gene therapy in SCID patients and its potential to become a more commonly used treatment.
  • Identify other current treatment options for SCID including HCT and enzyme replacement.
  • Discuss the need for ongoing studies to evaluate the long-term effects of current therapy alternatives. 

Program Description

This program will explore the use of gene therapy for severe combined immunodeficiency syndrome and discuss up to date advances in the field.  Other therapies including (Hematopoietic stem cell transplantation) HCT therapy and enzyme replacement will also be discussed.  The speaker will also address ongoing studies that are needed to reduce the late effects beyond survival with the current treatment options. 

Registration

   Program #
Single Viewer: Live Register18EL-348-2070
Single Viewer: On-Demand Register18EL-348-4070
Group Viewing: Live Register18EL-348-6070
Group Viewing: On-Demand Register18EL-348-8070
Group Viewing: Live & On-Demand Register18EL-348-9970

Speaker Biography

Dr. Jennifer Heimall is a graduate of UMDNJ-New Jersey Medical School where she also completed residencies in Internal Medicine and Pediatrics.  She then went on to complete a clinical and research fellowship in Allergy and Immunology at the National Institute of Health.  She is an Attending Physician in the Division of Allergy and Immunology at CHOP. 

Dr. Heimall’s expertise include Hyper IgE syndromes, post-transplant immune reconstitution, recurrent staphylococcal infections and atopic dermatitis, and appropriate transition of care from pediatric to adult physicians.  She is the recent author of a paper, “Long Term Outcomes of Severe Combined Immunodeficiency: Therapy Implications” published in the Expert Review of Clinical Immunology.